Anja Bogović

Anja Bogović

Auto-generated profile, based on publicly available information

Anja Bogović

Faculty of Medicine University of Belgrade Belgrade Serbia

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2025 in Srce i krvni sudovi
Verified
Journal Article
Open access
PDF file
ABAnja Bogović
Anja Bogović
STSara Tomović
Sara Tomović
NMNina Miljković
Nina Miljković
TSTomislav Smiljković
Tomislav Smiljković
IBIvan Busić
Ivan Busić
ADAleksandra Djokovic
Aleksandra Djokovic
Introduction: Primary antiphospholipid syndrome (PAPS) is a rare autoimmune disease characterized by arterial/venous thrombosis and/or obstetric pathology in the presence of antiphospholipid antibodies (aPL). Evidence suggests that aPL directly interact with membrane phospholipids of endothelial cells, leading to endothelial dysfunction (ED) and accelerating atherosclerosis. Methods: This study aimed to establish the presence of ED, expressed by a decrease in the percentage of flow-mediated brachial artery dilation (FMD), in a cohort of 100 Serbian PAPS patients without previously diagnosed cardiovascular disease. All participants underwent clinical evaluation to identify standard atherosclerotic risk factors. Tested aPL included: lupus anticoagulant (LA), anticardiolipin antibodies (aCL IgG/IgM), and anti-β2-glycoprotein I antibodies (a-β2GPI IgG/IgM). FMD was measured following standardized patient preparation and compared to results from 80 healthy controls. Results: The study cohort consisted predominantly of females age 47.7 ± 8.5 years with a low prevalence of conventional risk factors. ED, reflected by reduced FMD values, was present in 37.6% of PAPS patients, significantly more than in the control group (p = 0.0001). Age (p = 0.041) and glycemia value (p = 0.045) were significantly associated with ED. However, aPL type and clinical manifestations were not. Multivariate regression including age, glycemia value and thrombosis history showed no independent predictors of ED. Conclusion: ED is significantly more prevalent in PAPS patients than in healthy individuals, and represents a direct consequence of the autoimmune process. Earlier involvement of a cardiologist and appropriate management may reduce the risk of future cardiovascular complications.

1 January 2026 in Srce i krvni sudovi
Verified
Journal Article
Closed access
PDF file
LPLidija Pantić
Lidija Pantić
ABAnja Bogović
Anja Bogović
STSara Tomović
Sara Tomović
NMNina Miljković
Nina Miljković
TSTomislav Smiljković
Tomislav Smiljković
VVVladan Vukčević
Vladan Vukčević
Coronary artery disease (CAD) remains a leading cause of cardiovascular morbidity and mortality worldwide. Despite the fact that significant portion of patients remain asymptomatic, the absence of anginal symptoms does not exclude advanced disease, especially in patients with diabetes mellitus. Such patients often suffer from silent ischemia and unrecognized myocardial infarction. Consequently, early identification of high-risk asymptomatic individuals represents a major clinical challenge, as delayed recognition may lead to preventable adverse cardiovascular outcomes. We present the case of a 76-year-old male with multiple cardiovascular risk factors and asymptomatic multivessel CAD, who was diagnosed through a structured, risk-based diagnostic evaluation. Through this case, we illustrate the clinical pathway from initial presentation to advanced imaging and invasive assessment, emphasizing the importance of a proactive diagnostic strategy integrating anatomical and functional evaluation in high-risk asymptomatic patients.

1 January 2024 in Srce i krvni sudovi
Verified
Journal Article
Open access
PDF file
STSara Tomović
Sara Tomović
NMNina Miljković
Nina Miljković
ABAnja Bogović
Anja Bogović
TSTomislav Smiljković
Tomislav Smiljković
SDSrđan Dedić
Srđan Dedić
MBMarko Banovic
Marko Banovic
Heart failure with preserved ejection fraction (HFpEF) is a heterogeneous syndrome characterized by impaired left ventricular filling. It affects approximately 50% of patients with heart failure worldwide. Its complex pathophysiology involves the interaction between cardiomyocyte dysfunction and numerous comorbidities, including older age, female sex, type 2 diabetes, obesity, sleep apnea, hypertension, pulmonary hypertension, chronic obstructive pulmonary disease, coronary artery disease, and atrial fibrillation. Obesity, as a major risk factor, is chronic systemic inflammatory state that induces hemodynamic derangements and hormonal abnormalities that stress the cardiovascular system, with central obesity in women particularly contributing to HFpEF development. Diagnosis relies on clinical evaluation, measurement of natriuretic peptides, echocardiographic assessment, and exercise testing. Therapy includes SGLT-2 inhibitors, GLP-1 agonists, mineralocorticoid receptor antagonists, optimized diuretic therapy, management of comorbidities, lifestyle modifications, and structured exercise, improving prognosis and quality of life for patients.

1 January 2026 in Medicinska istrazivanja
Verified
Journal Article
Open access
PDF file
SASrdjan Aleksandric
Srdjan Aleksandric
NMNina Miljković
Nina Miljković
STSara Tomović
Sara Tomović
ISIvan Soldatovic
Ivan Soldatovic
SJStefan Juricic
Stefan Juricic
MBMarko Banovic
Marko Banovic
Introduction: When to intervene in asymptomatic patients with moderate or severe aortic stenosis (AS) and preserved left ventricular ejection fraction (LVEF) has not yet been determined. In patients with AS, low flow through the aortic valve is defined as indexed stroke volume (SVi) ≤35 ml/m2. Our work aimed to determine the relationship between SVi and all-cause mortality in asymptomatic patients with moderate or severe AS, concordantly high mean gradient across the aortic valve (Pmean), and preserved LVEF. Methods: The study included 121 asymptomatic patients (69 men, mean age 66±11) with moderate-to-severe AS (aortic valve area ≤1.5 cm2), concordantly high Pmean (≥30 mmHg), and preserved LVEF (≥50%). The median follow-up was 38 months (IQR 35-42 months). Results: Ten patients (8%) died during the follow-up. All-cause mortality was significantly higher in the group of AS-patients with SVi ≤35 ml/m2 compared to those with SVi >35 ml/m2 (15% vs. 4%, p=0.045). The cumulative incidence of all-cause mortality was significantly higher in the group of AS-patients with SVi ≤35 ml/m2 compared to those with SVi >35 ml/m2 (log-rank p=0.035). The group of AS-patients with SVi ≤35 ml/m2 had a 3.8-fold higher risk of all-cause mortality during long-term follow-up compared with those with SVi >35 ml/m2 (HR: 3.845; 95% CI: 1.004-14.871; p=0.041). Conclusion: Left ventricular SVi may be a significant predictor of all-cause mortality during long-term follow-up in asymptomatic patients with moderate or severe AS, concordantly elevated Pmean, and preserved LVEF. Larger studies are needed to confirm these findings.